Our experience after 1765 intravitreal injections of bevacizumab: the importance of being part of a developing story.
Semin Ophthalmol
; 22(2): 109-25, 2007.
Article
en En
| MEDLINE
| ID: mdl-17564934
This retrospective report describes our 20 months'experience using intravitreal injections of bevacizumab for the treatment of several retinal diseases. We describe our experience after 1765 intravitreal injections of bevacizumab in the treatment of different proliferative retinopathies - retinopathy of prematurity, choroidal neovascularization, diabetic retinopathy, among others. We believe that the findings reported in this study move us closer to a better treatment for different pathologies. However, further studies need to be performed in order to determine the safety and long-term efficacy of intravitreal bevacizumab either as first line therapy, after failure of conventional therapy, or in combination with conventional therapy.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Enfermedades de la Retina
/
Neovascularización Coroidal
/
Inhibidores de la Angiogénesis
/
Anticuerpos Monoclonales
Tipo de estudio:
Observational_studies
Límite:
Humans
/
Newborn
Idioma:
En
Revista:
Semin Ophthalmol
Asunto de la revista:
OFTALMOLOGIA
Año:
2007
Tipo del documento:
Article
País de afiliación:
México
Pais de publicación:
Reino Unido